|
Nov 14
|
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
|
|
Nov 14
|
Curis: Q3 Earnings Snapshot
|
|
Nov 14
|
Curis Provides Third Quarter 2024 Business Update
|
|
Oct 9
|
Curis Inc (CRIS) Q2 2024 Earnings Call Highlights: Promising Clinical Progress Amid Financial ...
|
|
Jul 25
|
Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
|
|
May 14
|
Curis Announces Additional Data from TakeAim Leukemia Study
|
|
May 10
|
Curis to Present Updated Data from the TakeAim Leukemia Study
|
|
May 8
|
Curis, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call Transcript
|
|
May 7
|
Curis Provides First Quarter 2024 Business Update
|
|
Apr 5
|
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
|
|
Apr 5
|
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
|
|
Apr 4
|
Curis to Present at Upcoming Healthcare Conferences in April
|
|
Feb 9
|
Curis, Inc. (NASDAQ:CRIS) Q4 2023 Earnings Call Transcript
|
|
Feb 8
|
Curis Provides Fourth Quarter 2023 Business Update
|
|
Dec 18
|
Curis, Inc. (NASDAQ:CRIS) Surges 54% Yet Its Low P/S Is No Reason For Excitement
|
|
Dec 12
|
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
|
|
Dec 11
|
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
|
|
Dec 6
|
Curis Announces Three Presentations at ASH
|
|
Dec 5
|
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
|
|
Nov 3
|
Curis, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Call Transcript
|